Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation
Cells · 2023
DOI: 10.3390/cells12081195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Branco M H Heuts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Department of Molecular Biology, Radboud University, 6525 GA Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Pluripotent Stem Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Kinderen Kankervrij.
Abstract (Originalsprache)
A t(9;11)(p22;q23) translocation produces the MLL-AF9 fusion protein, which is found in up to 25% of de novo AML cases in children. Despite major advances, obtaining a comprehensive understanding of context-dependent MLL-AF9-mediated gene programs during early hematopoiesis is challenging. Here, we generated a human inducible pluripotent stem cell (hiPSC) model with a doxycycline dose-dependent MLL-AF9 expression. We exploited MLL-AF9 expression as an oncogenic hit to uncover epigenetic and transcriptomic effects on iPSC-derived hematopoietic development and the transformation into (pre-)leukemic states. In doing so, we observed a disruption in early myelomonocytic development. Accordingly, we identified gene profiles that were consistent with primary MLL-AF9 AML and uncovered high-confidence MLL-AF9-associated core genes that are faithfully represented in primary MLL-AF9 AML, including known and presently unknown factors. Using single-cell RNA-sequencing, we identified an increase of CD34 expressing early hematopoietic progenitor-like cell states as well as granulocyte-monocyte progenitor-like cells upon MLL-AF9 activation. Our system allows for careful chemically controlled and stepwise in vitro hiPSC-derived differentiation under serum-free and feeder-free conditions. For a disease that currently lacks effective precision medicine, our system provides a novel entry-point into exploring potential novel targets for personalized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Department of Molecular Biology, Radboud University, 6525 GA Nijmegen, The Netherlands.
- Radboud University Medical Center, Department of Laboratory Medicine, Laboratory of Hematology, 6525 GA Nijmegen, The Netherlands.
ORCID-Profile: Branco M H Heuts, Saioa Arza-Apalategi, Sinne G Alkema
Förderung
- Stichting Kinderen Kankervrij
Zitieren
APA
Heuts, B. M. H., Arza-Apalategi, S., Alkema, S. G., Tijchon, E., Jussen, L., Bergevoet, S. M., van der Reijden, B. A., & Martens, J. H. A. (2023). Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation. Cells. https://doi.org/10.3390/cells12081195
Vancouver
Heuts BMH, Arza-Apalategi S, Alkema SG, Tijchon E, Jussen L, Bergevoet SM, et al. Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation. Cells. 2023. doi:10.3390/cells12081195
BibTeX
@article{Heuts2023,
author = {Heuts, Branco M H and Arza-Apalategi, Saioa and Alkema, Sinne G and Tijchon, Esther and Jussen, Laura and Bergevoet, Saskia M and van der Reijden, Bert A and Martens, Joost H A},
title = {Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12081195}
}
EUVIMED